• Aucun résultat trouvé

Clinical utility of amyloid PET imaging in the differential diagnosis of atypical dementias and its impact on caregivers

N/A
N/A
Protected

Academic year: 2021

Partager "Clinical utility of amyloid PET imaging in the differential diagnosis of atypical dementias and its impact on caregivers"

Copied!
47
0
0

Texte intégral

Loading

Figure

Table 1. Patient characteristics.
Table 3. Effect of amyloid scan on treatment and patient management.
Figure 1. Proposed investigative sequence in complex/atypical dementia cases.
Figure 2. Assessment of the impact of amyloid imaging on the diagnostic process and main caregiver
+4

Références

Documents relatifs

AUC, area under the ROC curve; DP, proton density-weighted; HC, healthy controls; MRPI, Magnetic Resonance Parkinsonism Index; MSA, multiple system atrophy; MSA-C, cerebellar variant

116,153 Harris and colleagues 153 proposed that ox- idative stress induced by the amyloid β peptide damages glu- tamate transporters, preventing glutamate uptake, and

Even in those cases where data are combined either axially (larger spans) or angularly (sinogram mashing), the resultant data are still acquired in a series of sinograms that

Highly realistic PET and SPECT images can be simulated using the Monte Carlo approach, by using ultra-high resolution activity maps as input. (regardless of

The amyloid PET reading has been classically implemented as a binary lecture, i.e., negative or positive for amyloidosis, however the current clinical experience has shown that

Most of the changes in diagnosis due to amyloid-PET or tau-PET presented as the second exam were observed in patients with discordant PET results (in 6 out of 8, and 11 out of 12

Image assessment was based on a structured scheme depicting four regions of interest (ROIs) corresponding to the neuropathological stages defined by Braak for tau deposition, shown

The Amy- loid Imaging to Prevent Alzheimer’s Disease Prognostic and Natural History Study (AMYPAD PNHS) is designed to determine amyloid PET imaging’s role in assessing AD risk